922 resultados para Einsiedeln, Switzerland (Benedictine monastery). Library.
Resumo:
Nos. XV-XVIII from v. 6 of the series.
Resumo:
Extract from the edition of 1834 ([8] p.) inserted before p. [7]
Resumo:
El presente trabajo realiza una revisión crítica del modelo formulado por Patrick Geary para la interpretación de los procesos conflictuales en la sociedad medieval, tomando como caso de estudio el Reino de León. A partir del análisis de los conflictos que enfrentaron al monasterio benedictino de Sahagún con los laicos en los siglos XI y XII, se examinan dos nociones que atraviesan este modelo. Por un lado, la concepción del conflicto como mecanismo de regulación de las relaciones sociales. Por otro, su carácter ahistórico, desvinculado de los procesos de cambio social dentro de los que se inscribe.
Resumo:
El presente trabajo realiza una revisión crítica del modelo formulado por Patrick Geary para la interpretación de los procesos conflictuales en la sociedad medieval, tomando como caso de estudio el Reino de León. A partir del análisis de los conflictos que enfrentaron al monasterio benedictino de Sahagún con los laicos en los siglos XI y XII, se examinan dos nociones que atraviesan este modelo. Por un lado, la concepción del conflicto como mecanismo de regulación de las relaciones sociales. Por otro, su carácter ahistórico, desvinculado de los procesos de cambio social dentro de los que se inscribe.
Resumo:
Appendix (p. 65-68): De monasterio Tubrensi.
Resumo:
Vol. 44-<61> called "neue folge."
Resumo:
"Separat-Abdruck aus dem Freiburger Diöcesan-Archiv, VIII. Band."
Resumo:
"Aus dem sechsten Bande der Beyträge zur Geschichte [etc.] des Erzbisthums München und Freysing besonders abgedruckt."
Resumo:
"Die Benedictiner-abtey zu den Schotten," pp. [63]-148.
Resumo:
Mode of access: Internet.
Resumo:
Mode of access: Internet.
Resumo:
Bibliographical foot-notes.
Resumo:
Ascidians are marine invertebrates that have been a source of numerous cytotoxic compounds. Of the first six marine-derived drugs that made anticancer clinical trials, three originated from ascidian specimens. In order to identify new anti-neoplastic compounds, an ascidian extract library (143 samples) was generated and screened in MDA-MB-231 breast cancer cells using a real-time cell analyzer (RTCA). This resulted in 143 time-dependent cell response profiles (TCRP), which are read-outs of changes to the growth rate, morphology, and adhesive characteristics of the cell culture. Twenty-one extracts affected the TCRP of MDA-MB-231 cells and were further investigated regarding toxicity and specificity, as well as their effects on cell morphology and cell cycle. The results of these studies were used to prioritize extracts for bioassay-guided fractionation, which led to the isolation of the previously identified marine natural product, eusynstyelamide B (1). This bis-indole alkaloid was shown to display an IC50 of 5 μM in MDA-MB-231 cells. Moreover, 1 caused a strong cell cycle arrest in G2/M and induced apoptosis after 72 h treatment, making this molecule an attractive candidate for further mechanism of action studies.
Resumo:
On April, 23rd 2007 a series of postings started on Infobib.de, where guest authors from all over the world introduced the library and library related blogs of their own country. This book is a collection of 30 revised LibWorld articles, accompanied by a foreword by Walt Crawford. Included are articles about the blogosphere of: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Canada, Denmark, Finland, France, Greece, Hungary, Iran, Italy, Japan, Latvia, Malawi, Netherlands, New Zealand, Norway, Peru, Puerto Rico, Russia, Singapore, Spain, Sweden, Switzerland, Trinidad & Tobago, USA.
Resumo:
The economic burden associated with osteoporosis is considerable. As such, cost-effectiveness analyses are important contributors to the diagnostic and therapeutic decision-making process. The aim of this study was to review the cost effectiveness of treating post-menopausal osteoporosis with bisphosphonates and identify the key factors that influence the cost effectiveness of such treatment in the Swiss setting. A systematic search of databases (MEDLINE, EMBASE and the Cochrane Library) was conducted to identify published literature on the cost effectiveness of bisphosphonates in post-menopausal osteoporosis in the Swiss setting. Outcomes were compared with similar studies in Western European countries. Three cost-effectiveness studies of bisphosphonates in this patient population were identified; all were from a healthcare payer perspective. Outcomes showed that, relative to no treatment, treatment with oral bisphosphonates was predicted to be cost saving for most women aged ≥70 years with osteoporosis or at least one risk factor for fracture, and cost effective for women aged ≥75 years without prior fracture when used as a component of a population-based screen-and-treat programme. Results were most sensitive to changes in fracture risk, cost of fractures, cost of treatment, nursing home admissions and adherence with treatment. Swiss results were generally comparable to those in other European settings. Assuming similar clinical efficacy, lowering treatment cost (through the use of price-reduced brand-name or generic drugs) and/or improving adherence should both contribute to further improving the cost effectiveness of bisphosphonates in women with post-menopausal osteoporosis. Published evidence indicates that bisphosphonates are estimated to be similarly cost effective or cost saving in most treatment scenarios of post-menopausal osteoporosis in Switzerland and in neighbouring European countries.